Quantcast
Home > Quotes > TRXC
x

TransEnterix, Inc. Common Stock (TRXC) Quote & Summary Data

TRXC 
$4.5
*  
0.07
1.53%
Get TRXC Alerts
*Delayed - data as of Oct. 18, 2018  -  Find a broker to begin trading TRXC now
Exchange:AMEX
Industry: Health Care
Community Rating:
View:    TRXC Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
6.25
Today's High / Low
$ 4.80 / $ 4.34
Share Volume
5,138,227
90 Day Avg. Daily Volume
7,164,637
Previous Close
$ 4.57
52 Week High / Low
$ 6.98 / $ 1.27
Market Cap
940,358,408
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.1

Intraday Chart

Shares Traded

Share Volume:
5,138,227
90 Day Avg. Daily Volume:
7,164,637

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.83

Trading Range

The current last sale of $4.50 is 254.33% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.80 $ 6.98
 Low: $ 4.34 $ 1.27

Company Description (as filed with the SEC)

TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The Company is focused on the commercialization of the Senhance(TM) Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance System has been granted a CE Mark in Europe for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery. In April 2017, the Company submitted a 510(k) application to the FDA for the Senhance System.  ... More ...  


Risk Grade

Where does TRXC fit in the risk graph?


Risk Grade Scale

Consensus Recommendation

Analyst Info